Evidence map›Paper›PMID 41998635›Full record

ArticleJournal of translational medicine2026

18-β-glycyrrhetinic acid facilitates nuclear-mitochondrial communications to alleviate oxidative stress through HMGB1-cGAS-Mul1 axis in tendinopathy.

Yuan-Yuan Gao, Wen-Shuang Sun, Zi-Ying Sun, Jun-Rui Wang, Zhong-Yang Lv, Yu-Jia Li, Hao-Yuan Tian, Zheng-Yang Bao, Xin-Ran Qiu, Zheng Wang and 4 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuan-Yuan Gao *Department of Orthopaedics, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Wen-Shuang Sun *Department of Orthopaedics, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Zi-Ying Sun *Department of Orthopaedics, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Jun-Rui WangJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China.
Zhong-Yang LvDepartment of Orthopaedics, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Yu-Jia LiDepartment of Pharmacy, Nantong Third People's Hospital, Nantong, China.
Hao-Yuan TianJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China.
Zheng-Yang BaoJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China.
Xin-Ran QiuJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China.
Zheng WangState Key Laboratory of Pharmaceutical Biotechnology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China.
Shi-Zhong ZhengJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China.
Jiang-Juan ShaoJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China. jjshao@njucm.edu.cn.
Zi-Li ZhangJiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Media, Nanjing University of Chinese Medicine, Nanjing, China. zilizhang@njucm.edu.cn.
Jia MengDepartment of Orthopaedics, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China. michaelmengjia@163.com.

Funding

general Project of the Natural Science Research of Jiangsu Higher Education Institutions 23KJB310017Leading Program for First Class Disciplines at Nanjing University of Traditional Chinese Medicine ZYXYL2024-008National Key Laboratory of Traditional Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacturing Technology Research Innovation Project NZYSKL240102National Natural Science Foundation of China 82274185, 882374124, 82173874, 82474164Natural Science Foundation of Jiangsu Province BK20230458Program of Jinling hospital 2024JCYJQN096, 2023JCYJYB100Traditional Chinese Medicine Cancer Poison Disclosure and Leading Project AD202403
6 · The paper itself

Abstract

backgroundTendinopathy is a prevalent orthopaedic condition characterized by disrupted tendon homeostasis, with oxidative stress being a key contributing mechanism. Although the natural compound 18-β-Glycyrrhetinic acid (GA) exhibits antioxidant properties and is a therapeutic candidate for tendinopathy, its precise molecular mechanism remains unclear. This study aimed to elucidate how GA alleviates tendinopathy, with a focus on its role in regulating the HMGB1-cGAS-STING axis and NLRP3 inflammasome activation in the context of oxidative stress.

methodsWe employed single-cell RNA sequencing (scRNA-seq) of clinical samples, proteomics of animal tissues, and comprehensive pharmacological assays to investigate the mechanisms of tendinopathy. Furthermore, the rat tendinopathy model and H

resultsWe found that GA significantly reduced oxidative stress and subsequent inflammation, thereby mitigating collagen disruption in rats with tendinopathy. Notably, scRNA-seq revealed that the proportion of TSCs increased significantly during tendinopathy, which were particularly susceptible to reactive oxygen species (ROS). TSCs from oxidative damage and inhibited activation of the NLRP3 inflammasome by suppressing the cGAS-STING pathway. Mechanistically, GA promoted cGAS degradation by enhancing its interaction with the mitochondrial E3 ubiquitin ligase Mul1. This effect was mediated through high-mobility group box 1 (HMGB1), as GA disrupted the HMGB1-cGAS interaction. Specifically, GA induced methylation of HMGB1 at lysine 43, a modification essential for its activity. This methylation was catalyzed by the methyltransferase DOT1L, which was upregulated and directly bound by GA. Collectively, GA alleviates tendinopathy by targeting the DOT1L-HMGB1-cGAS axis to resolve oxidative stress and inflammation.

conclusionCollectively, our findings provide new insights into how oxidative stress accelerates tendinopathy progression. Moreover, they delineate the mechanism by which GA in mitigates oxidative damage and inflammation in TSCs by inhibiting the co-localization of HMGB1 and cGAS. Overall, this study offers scientific support for further developing GA as a promising therapeutic agent for tendinopathy treatment.

Indexed as

Cell NucleusGlycyrrhetinic AcidHMGB1 ProteinMitochondriaOxidative StressSignal TransductionAnimalsHumansMaleNLR Family, Pyrin Domain-Containing 3 ProteinRatsRats, Sprague-DawleyStem Cells18alpha-glycyrrhetinic acidGlycyrrhetinic AcidHMGB1 ProteinNLR Family, Pyrin Domain-Containing 3 Protein18-β-Glycyrrhetinic acidcGAS-STINGHMGB1 methylationNLRP3 inflammasomeOxidative stressTendinopathy

Identifiers

PMID41998635
PMCPMC13091248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.